IVD Conformity Assessment in Russia From September 1, 2026

1. Key takeaways

From September 1, 2026, Order No. 421n of the Ministry of Health of Russia, dated May 13, 2026, restructures the conformity assessment of in vitro diagnostic devices: certain reagents, calibrators, control materials, wash solutions, diluents, culture media and certain plastic consumables no longer require technical testing, and the centre of gravity of the assessment shifts to clinical laboratory testing. At the same time, the patient biological material used in testing must come from the relevant reference population within Russia, and the test result documents may be issued in electronic form. Together these changes redraw the evidence plan for every IVD project starting in autumn 2026.

For sponsors, the effect is a rebalancing rather than a simplification. Budget previously reserved for bench testing of exempted categories moves to protocol design, local specimen logistics and the clinical laboratory programme. Projects that begin with a clear exemption check and an early agreement on biological material sourcing will run to a predictable schedule; projects that discover these requirements late will lose months securing specimens inside Russia.

The list of exempted categories should be read against the nomenclature classification of Order No. 4n, because the exemption follows the type code of the product and not its marketing name. Reagents that appear similar commercially can sit in different type codes, with different consequences for the testing plan. Where a product family contains both exempted and non-exempted items, the evidence plan should be built item by item rather than family by family, and the classification decision should be documented in the dossier so that the expert organisation can verify the exemption claim without additional queries.

2. Legal basis

The instruments governing IVD conformity assessment under the new procedures are summarised below.

3. Expert insights

Insight 1: removing one stage does not lower review intensity. The exemption removes specific physicochemical verification steps for listed categories, but the clinical laboratory testing requirements for protocol design are in fact more detailed: the plan must state the type of evaluation, the trial schedule, the stages and timing, and must include the device information. A thin protocol that would previously have passed under the general umbrella of technical testing will now be sent back for supplementation. Sponsors should treat the protocol as the core regulatory document of the project and invest review cycles in it before submission, not after comments arrive.

Insight 2: local biological material becomes a hard requirement. The procedures require the use of biological material obtained within Russia from the relevant reference population, which may be residual, archived or specifically collected samples. Existing overseas clinical data cannot substitute for this element in the IVD scenario. This makes specimen sourcing a critical-path task: agreements with Russian laboratories, ethics considerations for residual sample use and the logistics of specimen transfer all take time, and none of it can be started too early.

Insight 3: IVDs for emerging and rare infections gain a new alternative path. Beyond reference strains, the use of genetically engineered samples is permitted in specific situations. For developers of diagnostic tests targeting newly emerging infectious diseases, where native positive specimens are scarce or inaccessible, this flexibility can materially improve project scheduling. The applicability of the alternative path should be confirmed with the testing laboratory and documented, so that the expert organisation sees a justified methodological choice rather than a gap in specimens.

Electronic issuance of result documents also has an organisational side. Laboratories must be able to produce signed electronic documents, and the sponsor must be able to receive, store and submit them in the form accepted by the registration workflow. Agreeing the electronic document format, the signing method and the transmission channel with the laboratory at contracting avoids a situation in which paper originals are requested late in the project. Because reporting to the RZN automated information system is part of the new design, the electronic readiness of the whole evidence chain is not optional but a structural requirement of the reformed procedure.

4. Practical recommendations

1. At project start, check whether the product falls within the list of categories exempt from technical testing; if it does, recalculate the testing budget and timeline accordingly.
2. Sign an agreement with a Russian laboratory for the acquisition of biological material early, and treat it as a critical-path task in the project plan.
3. Prepare all test records in electronic form to align with the subsequent reporting arrangements to the RZN automated information system.
4. Draft the clinical laboratory testing protocol with every element required by Order No. 421n, including evaluation type, schedule, stages and timing, and device information.
5. Assess whether the genetically engineered sample alternative applies to your assay, and document the justification for the chosen specimen strategy.

5. Verification checklist

• □ It has been confirmed that the product falls within the list exempt from technical testing
• □ A written agreement exists for the sourcing of biological material from the local reference population
• □ The clinical laboratory testing plan has been prepared with the elements listed in Order No. 421n
• □ Whether alternative paths such as genetically engineered samples apply has been assessed
• □ Electronic result documents and the reporting process are ready

Regulatory information verified as of October 29, 2026.

GRZAN helps IVD manufacturers navigate the reformed Russian conformity assessment procedures, from exemption analysis and clinical laboratory testing protocol design to the arrangement of local biological material sourcing and electronic reporting to the RZN information system. Our consultants keep your IVD evidence plan aligned with the requirements in force from September 1, 2026. For support with Russian IVD registration and conformity documentation, contact us at info@grzanglobal.com.